MK-2206 2HCl是一种可口服的、特异选择性的Akt抑制剂，在无细胞试验中MK-2206 2HCl对Akt1/2/3的IC₅₀值分别是8 nM/12 nM/65 nM；MK-2206 2HCl是第一个进入临床研究阶段的Akt小分子变构抑制剂。MK-2206 2HCl在肿瘤细胞中可诱导细胞凋亡和细胞自噬。

参考文献

[1]. Hirai H, et al. MK-2206, an allosteric Akt inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo. Mol Cancer Ther. 2010 Jul;9(7):1956-67.

[2]. Cheng Y, et al. eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206. Cancer Res. 2011 Apr 1;71(7):2654-63.

[3]. Cui H, et al. The AKT inhibitor MK2206 suppresses airway inflammation and the pro‑remodeling pathway in a TDI‑induced asthma mouse model. Mol Med Rep. 2020 Nov;22(5):3723-3734.

冰袋运输。粉末直接保存于-20℃，有效期3年。建议分装后-20℃干燥保存，避免反复冻融。